Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in ...
The FDA has approved Enspryng (satralizumab-mwge) for thyroid eye disease in adults, offering the first at-home subcutaneous IL-6 receptor antagonist for TED.
Nationwide initiative brings thyroid awareness, health education, targeted TSH screening and referral closer to the community ...
The FDA approved satralizumab-mwge (Enspryng; Genentech) on October 15, 2026, for adults with thyroid eye disease (TED) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results